share_log

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61

RBC Capital維持對ideaya生物科學的跑贏大盤評級,將目標價上調至61美元。
Benzinga ·  07/11 10:53

RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $53 to $61.

RBC Capital分析師Gregory Renza維持對ideaya生物科學(納斯達克:IDYA)的Outperform評級,將目標價從53美元提高至61美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論